On June 29, PegBio rose 17.94% in regular trading, trading at HK$5.86/share, with turnover of HK$97.03 million.

On the news front, the company completed its H-share full circulation on June 25, converting approximately 101.7 million previously unlisted shares into H-shares, which began trading on June 26. Following the conversion, H-shares as a proportion of total issued shares increased from 72.69% to 98.70%, while unlisted shares dropped from 106.8 million to just 5.09 million. The sudden influx of tradable shares created concentrated selling pressure on June 26, driving the stock to a historic low of HK$4.96. After the prior session absorbed the bulk of liquidation from newly unlocked shareholders, the stock staged a sharp technical rebound from depressed levels.

PegBio is a biotechnology company focused on developing innovative therapies for chronic diseases, with its core product Paidakang receiving marketing approval in November 2025 and a commercialization partnership with Tenry Pharmaceutical targeting cumulative sales exceeding RMB 10 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)